In a report issued on February 20, Evan Seigerman from Credit Suisse maintained a Buy rating on Amgen (AMGN), with a price target of $252.00. The company’s shares closed last Monday at $222.79.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 13.6% and a 56.0% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Aimmune Therapeutics, and Mirati Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen with a $248.73 average price target, implying an 11.9% upside from current levels. In a report issued on February 6, Argus Research also maintained a Buy rating on the stock with a $265.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $244.99 and a one-year low of $166.30. Currently, Amgen has an average volume of 2.22M.
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
